- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05522218
Eluvia DES for the Patients With Femoropopliteal Artery Lesions.
September 12, 2023 updated by: Ziheng Wu, MD, First Affiliated Hospital of Zhejiang University
Clinical Effectiveness and Health Economic Evaluation of Eluvia Drug-eluting Stent in the Treatment of Femoropopliteal Artery Lesions
This study is a multicenter, prospective, observational study, aiming to enroll 400 patients with peripheral arterial disease in the femoral-popliteal segment implanted with Eluvia stent.
Each patient was followed up for 2 years.
The technical success rate, target lesion patency rate, quality of life improvement, cost of Eluvia stent implantation, and other outcomes will be analysed.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
400
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Recruiting
- First Affiliated Hospital of Zhejiang University
-
Contact:
- Ziheng Wu, PhD
- Phone Number: 0571-87236745
- Email: wuziheng@zju.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
peripheral arterial disease patients implanted with Eluvia stent
Description
Inclusion Criteria:
- Rutherford Stage 2-5.
- At least 90% stenosis or occlusion of the femoropopliteal artery.
- Eluvia stents are used for target lesions.
- Agree and sign the informed consent form
Exclusion Criteria:
- Life expectancy is less than 1 year.
- Those with severe infection and gangrene of the limbs or those with tissue defects beyond the plane of the toes (ie major tissue loss), who may undergo major amputation even if the blood vessels are opened.
- Patients and their families are reluctant to join the observational study, or have difficulty in communication and are unable to assess the quality of life.
- Patients with in-stent restenosis of the femoral popliteal artery.
- Patients with acute arterial thrombosis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change of Rutherfor classification
Time Frame: 24 months
|
Comparison of preoperative Rutherford classification and postoperative Rutherford classification at 24 months
|
24 months
|
F-TLR
Time Frame: 24 months
|
free of target vascular reconstruction
|
24 months
|
limb salvage rate
Time Frame: 24 months
|
Proportion of patients without ambutation
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical success rate
Time Frame: 1 month
|
Percentage of patients with successful endovascular treatment without postoperative complications
|
1 month
|
the patency target lesion
Time Frame: 24 months
|
Restenosis was defined as PSVR > 2.4 as determined by vascular ultrasonography
|
24 months
|
mortality rate
Time Frame: 24 months
|
the propotion of death
|
24 months
|
the life quality change
Time Frame: 24 months
|
Amount by Vas-Qol questionare between perioperation and 24month postoperation
|
24 months
|
the life quality change
Time Frame: 24 months
|
Amount by EQ-5D5L questionare between perioperation and 24month postoperation
|
24 months
|
Economics Evaluation
Time Frame: 24 months
|
Cumulative hospitalization expenses related to treatment within 24 months
|
24 months
|
Wound Healing Evaluation
Time Frame: 24 months
|
If there is an ulcer wound, evaluate the ulcer wound healing at 24 months after surgery and before treatment
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2022
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
August 24, 2022
First Submitted That Met QC Criteria
August 28, 2022
First Posted (Actual)
August 30, 2022
Study Record Updates
Last Update Posted (Actual)
September 13, 2023
Last Update Submitted That Met QC Criteria
September 12, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIT20220166B-X1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
After recruitment, data will be shared after 2 years of follow-up
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vascular Diseases
-
Terumo Europe N.V.CompletedPeripheral Vascular Disease | Hemostasis | Vascular Closure | Endovascular ProcedureBelgium, France, Germany
-
University Hospital, MontpellierTerminated
-
Alvotech Swiss AGActive, not recruitingChorioretinal Vascular DiseaseGeorgia
-
AmgenCompletedChorioretinal Vascular DiseaseUnited States
-
Duke UniversityTerminatedRetinal Vascular DiseaseUnited States
-
University of California, IrvineUniversity of Oklahoma; US Department of Veterans Affairs; C. R. Bard; Long Beach...CompletedPeripheral Vascular Disease | Cardiac Catheterization | Vascular Access ComplicationsUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
Regeneron PharmaceuticalsCompletedChorioretinal Vascular DiseaseUnited States
-
Terumo Europe N.V.Terumo Medical CorporationRecruitingPeripheral Vascular Disease | Hemostasis | Vascular Closure | Femoral Artery | Endovascular ProcedureFrance, Germany, Netherlands
Clinical Trials on Eluvia drug eluting stent
-
Seoul National University Bundang HospitalKorea University Anam Hospital; Korea University Guro Hospital; Gachon University... and other collaboratorsCompletedMyocardial Ischemia | Coronary Artery DiseaseKorea, Republic of
-
Henan Institute of Cardiovascular EpidemiologyRecruiting
-
Fatebenefratelli and Ophthalmic HospitalCompletedCardiovascular Diseases
-
Aarhus University Hospital SkejbyMedtronic Cardiovascular; Biosensors InternationalCompletedCoronary Artery Disease | Angina PectorisDenmark
-
Hospital Universitari Vall d'Hebron Research InstituteB.Braun Surgical SACompleted
-
Medtronic VascularMedtronic Japan Co., Ltd.CompletedMyocardial Ischemia | Cardiovascular Diseases | Coronary Artery Disease | Arterial Occlusive DiseasesJapan
-
Boston Scientific CorporationLabcoat, Ltd.CompletedCoronary Artery DiseaseItaly
-
Yonsei UniversityCompletedSymptomatic Peripheral Artery Disease With Femoropopliteal Lesions | Moderate or Severe Claudication (Rutherford Category 2 or 3) | Critical Limb Ischemia (Rutherford Category 4 or 5)Korea, Republic of
-
University of SaskatchewanUnknown
-
Bon-Kwon KooSeoul St. Mary's Hospital; Chonnam National University Hospital; Seoul National... and other collaboratorsRecruitingCoronary Artery Disease | Multi Vessel Coronary Artery DiseaseKorea, Republic of